Effects of rosiglitazone treatment on TGF-β1/Smad signaling pathways in Otsuka Long-Evans Tokushima Fatty rat lungs

Wei Zhao,LiJuan Jiang,MengYu Zhu,Jia Liu,Yajing Zhang,Xiao Q. Chen,Hong Zhang
DOI: https://doi.org/10.3969/j.issn.0529-1356.2011.02.017
2011-01-01
Abstract:Objective: To approach the effects of rosiglitazone treatment on transforming growth factor-β1/Smad (TGF-β1/Smad) signaling pathways in Otsuka Long-Evans Tokushima Fatty( OLETF) rats. Methods: Experimental rats were divided into three groups: OLETF group, rosiglitazone-treated group(OLETF/L group) and Long Evans Tokushima Otsuka rats (LETO group) as control, 8 rats in each group. The expression of TGF-β1, Smad2, Smad3, Smad7, fibronectin(FN), and collagen type III in rat lungs were examined by immunohistochemistry. Results: The expressions of TGF-β1, Smad2, Smad3, FN and collagen type III increased in OLETF rat lungs than those of LETO rats (P < 0.01), while the expression of Smad7 decreased in OLETF group (P < 0.01). The expressions of TGF-β1, Smad2, Smad3, FN and collagen type III decreased in OLETF/L group than those of the OLETF group (P < 0.01), and the expression of Smad7 increased in OLETF/L group (P < 0.01). Conclusion: Rosiglitazone may improve diabetic pulmonary fibrosis probably by regulating TGF-β1/Smad signaling pathways.
What problem does this paper attempt to address?